moxifloxacin has been researched along with Arrhythmias, Cardiac in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (21.95) | 29.6817 |
| 2010's | 27 (65.85) | 24.3611 |
| 2020's | 5 (12.20) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, L; Sun, H | 1 |
| Caceres, M; Devinsky, O; Huddlestone, JR; Kasserra, C; Medlock, M; Morrison, R; O'Mara, E; Soni, P; Wan, Y | 1 |
| Bastogne, T; Champéroux, P; Fares, R; Le Guennec, JY; Richard, S; Thireau, J | 1 |
| Fujio, Y; Hamatani, T; Kaji, Y; Kakuyama, H; Kawai, H; Noda, N; Takagaki, T; Yodo, Y | 1 |
| Aghasafari, P; Bekker, S; Clancy, CE; Dawson, JRD; DeMarco, KR; Jeng, MT; Noskov, SY; Vorobyov, I; Yang, PC; Yarov-Yarovoy, V | 1 |
| Clausen, C; Cohen, IS; Cui, J; Gao, J; Grinter, SZ; Hou, P; Kang, PW; Liang, H; Lin, Y; Liu, Y; Lu, Z; Ma, Z; Shi, J; Wang, HZ; White, KM; Xu, X; Zhang, G; Zhao, L; Zhao, W; Zou, X | 1 |
| Ando, K; Cao, X; Izumi-Nakaseko, H; Matsukura, S; Naito, AT; Nakamura, Y; Sugiyama, A; Wada, T | 1 |
| Bando, K; Deguchi, J; Honda, Y; Watanabe, H; Yamada, T | 1 |
| Cho, Y; Park, HS | 1 |
| Benson, C; Brown, R; Couderc, JP; Darpo, B; Dota, C; Ferber, G; Ferry, J; Jarugula, V; Keirns, J; Ortemann-Renon, C; Pham, T; Riley, S; Sarapa, N; Ticktin, M; Zareba, W | 1 |
| Bouchard, A; Carr, DB; Hamilton, DA; Lacouture, PG; Lang, E; Madden, D; McDonnell Moorehead, T; Sprenger, CR; Wright, C | 1 |
| Farmer, HF; Johnson-Levonas, AO; Lai, E; Larson, P; Lauring, B; Li, XS; Liu, Y; Moreau, A; Wagner, JA | 1 |
| Dingemanse, J; Lindegger, N; Reseski, K; Sidharta, PN | 1 |
| Fossa, AA; Martin, P; Purkayastha, J; Robinson, A; Zhou, M | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Cools, F; Danhof, M; Gallacher, DJ; Gotta, V; Morissette, P; Sannajust, F; van Ammel, K; van der Graaf, PH; Visser, SA | 1 |
| Bowman, J; Chen, X; Punwani, N; Soloviev, M; Williams, W; Yeleswaram, S | 1 |
| Darpo, B; Fernandes, P; Jamieson, BD; Keedy, K; Oldach, D; Sager, PT; Zhou, M | 1 |
| Colucci, S; Harris, SC; Morganroth, J; Ripa, SR; Thorn, MD | 1 |
| Baum, C; Bello, CL; Dinolfo, M; Huang, X; Levine, S; Mulay, M; Patyna, S; Rosen, L; Toh, M; Van Vugt, A | 1 |
| Dang, Q; Ng, MJ; Yan, LK; Zhang, J | 1 |
| Sethuraman, V; Wang, J; Wu, S | 1 |
| Quan, H; Sun, GG | 1 |
| Garnett, C; Wang, Y | 1 |
| Abt, M; Derks, M; Meneses-Lorente, G; Mwangi, A | 1 |
| de Kam, PJ; Peeters, P; Prohn, M; Thomsen, T; van Kuijk, J | 1 |
| Bowen, C; Jenkins, JM; Matthys, G; McGuire, S; Park, JW; Peng, B; Williams, D; Wire, MB; Zhang, J | 1 |
| Florian, J; Garnett, CE; Gobburu, JV; Li, M; Tornøe, CW; Wang, Y | 1 |
| Grosjean, P; Urien, S | 1 |
| Alvey, C; Choo, HW; Cuozzo, C; Damle, B; Kirby, D; Labadie, RR; Riley, S | 1 |
| Couderc, JP; Darpo, B; Davis, JD; Fossa, AA; Langdon, G; Wallis, R; Wilson, F; Zhou, M | 1 |
| Andersen, MP; Graff, C; Højer, AM; Kallio, A; Kanters, JK; Matz, J; Struijk, JJ; Toft, E; Vainio, PJ | 1 |
| Annes, W; Ayan-Oshodi, M; Chiesa, J; Hall, SD; Seger, M; Willis, BA; Zhang, W | 1 |
| Fijorek, K; Kawecka-Jaszcz, K; Klima, Ł; Patel, N; Polak, S; Stolarz-Skrzypek, K | 1 |
| Bradley, JA; Cass, JD; Chen, X; Dahm, CM; Engwall, MJ; Kadyszewski, E; Sun, Z; Zhou, J | 1 |
| Crimin, K; Engtrakul, J; Fermini, B; Fossa, AA; O'Donnell, J; Wisialowski, T | 1 |
| Attevelt, NJ; Beekman, JD; Chiba, K; Sugiyama, A; Takahara, A; Thomsen, MB; Vos, MA | 1 |
| Falagas, ME; Rafailidis, PI; Rosmarakis, ES | 1 |
| Bridson, WE; Hulhoven, R; Meeus, MA; Rosillon, D; Salas, E; Stockis, A | 1 |
| Anderson, ME; Mazur, A; Roden, DM; Yang, T | 1 |
| Cox, BF; Gintant, GA; Limberis, JT; McDermott, JS; Wegner, CD | 1 |
2 review(s) available for moxifloxacin and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.
Topics: Animals; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fluoroquinolones; Heart Conduction System; Heart Rate; Humans; Long QT Syndrome; Male; Moxifloxacin; Phenethylamines; Potassium Channel Blockers; Reproducibility of Results; Sotalol; Sulfonamides; Telemetry; Translational Research, Biomedical | 2015 |
Arrhythmias associated with fluoroquinolone therapy.
Topics: Anti-Bacterial Agents; Arrhythmias, Cardiac; Aza Compounds; Drug Interactions; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Moxifloxacin; Quinolines; Risk Factors; Torsades de Pointes | 2007 |
21 trial(s) available for moxifloxacin and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; Arrhythmias, Cardiac; CCR5 Receptor Antagonists; Central Nervous System; Electrocardiography; Electroencephalography; Female; Heart; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyrimidines; Ritonavir; Young Adult | 2010 |
Thorough QT/QTc Study Shows That a Novel 5-HT
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Arrhythmias, Cardiac; Asian People; Benzamides; Case-Control Studies; Cisapride; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Humans; Indoles; Irritable Bowel Syndrome; Long QT Syndrome; Male; Morpholines; Moxifloxacin; Piperidines; Placebos; Serotonin 5-HT4 Receptor Agonists; Serotonin Receptor Agonists | 2020 |
Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC Study.
Topics: Arrhythmias, Cardiac; Biomarkers; Cetirizine; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Indoles; Ion Channels; Long QT Syndrome; Male; Moxifloxacin; Ondansetron; Phenethylamines; Quinine; Quinolizines; Risk Assessment; Sulfonamides | 2020 |
Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arrhythmias, Cardiac; Aza Compounds; beta-Cyclodextrins; Cross-Over Studies; Diclofenac; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Fluoroquinolones; HEK293 Cells; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Quinolines; Young Adult | 2013 |
Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anticholesteremic Agents; Arrhythmias, Cardiac; Cholesterol Ester Transfer Proteins; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Investigational; Electrocardiography; Female; Fluoroquinolones; Heart; Humans; Male; Middle Aged; Models, Biological; Moxifloxacin; Oxazolidinones; Topoisomerase II Inhibitors; Young Adult | 2014 |
Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
Topics: Adult; Arrhythmias, Cardiac; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Endothelin Receptor Antagonists; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Pyrimidines; Sulfonamides; Young Adult | 2014 |
Use of ECG restitution (beat-to-beat QT-TQ interval analysis) to assess arrhythmogenic risk of QTc prolongation with guanfacine.
Topics: Adrenergic alpha-2 Receptor Agonists; Arrhythmias, Cardiac; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Guanfacine; Humans; Long QT Syndrome; Male; Moxifloxacin; Reference Values; Retrospective Studies; Risk Assessment | 2014 |
Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study.
Topics: Action Potentials; Adolescent; Adult; Anti-Bacterial Agents; Arrhythmias, Cardiac; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Moxifloxacin; Nitriles; Pyrazoles; Pyrimidines; Risk Assessment; Time Factors; Young Adult | 2014 |
Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjects.
Topics: Arrhythmias, Cardiac; Cross-Over Studies; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Humans; Macrolides; Male; Moxifloxacin; Placebos; Triazoles | 2017 |
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Topics: Administration, Cutaneous; Adult; Arrhythmias, Cardiac; Aza Compounds; Buprenorphine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoroquinolones; Healthy Volunteers; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Naltrexone; Pain; United States; Young Adult | 2017 |
Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Aza Compounds; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Granisetron; Heart Ventricles; Humans; Indoles; Moxifloxacin; Neoplasms; Placebos; Protein-Tyrosine Kinases; Pyrroles; Quinolines; Risk; Sunitinib; Time Factors | 2009 |
Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
Topics: Administration, Oral; Adult; Amides; Anticholesteremic Agents; Area Under Curve; Arrhythmias, Cardiac; Aza Compounds; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Confidence Intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Esters; Fluoroquinolones; Heart; Humans; Male; Metabolic Clearance Rate; Middle Aged; Moxifloxacin; Quinolines; Sulfhydryl Compounds; Young Adult | 2010 |
Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
Topics: Adolescent; Adult; Androstanols; Arrhythmias, Cardiac; Aza Compounds; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; gamma-Cyclodextrins; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Models, Biological; Moxifloxacin; Neuromuscular Nondepolarizing Agents; Quinolines; Risk Assessment; Risk Factors; Rocuronium; Sugammadex; Time Factors; Vecuronium Bromide; Young Adult | 2010 |
Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.
Topics: Adolescent; Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Benzoates; Dose-Response Relationship, Drug; Electrocardiography; Epidemiologic Methods; Female; Fluoroquinolones; Heart Rate; Humans; Hydrazines; Male; Middle Aged; Moxifloxacin; Pyrazoles; Quinolines; Treatment Outcome; Young Adult | 2010 |
Creation of a knowledge management system for QT analyses.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Arrhythmias, Cardiac; Aza Compounds; Cross-Over Studies; Diagnosis, Computer-Assisted; Dose-Response Relationship, Drug; Drugs, Investigational; Electrocardiography; Electronic Data Processing; Female; Fluoroquinolones; Humans; Knowledge Management; Male; Middle Aged; Moxifloxacin; Quinolines; Risk Assessment; United States; United States Food and Drug Administration; Young Adult | 2011 |
Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.
Topics: Adolescent; Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Body Composition; Body Weight; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Male; Middle Aged; Models, Biological; Moxifloxacin; Quinolines; Tissue Distribution; Young Adult | 2012 |
Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation.
Topics: Acetamides; Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Linezolid; Male; Middle Aged; Moxifloxacin; Oxazolidinones; Quinolines; Young Adult | 2011 |
The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
Topics: Anti-Infective Agents; Arrhythmias, Cardiac; Autonomic Nervous System; Aza Compounds; Cross-Over Studies; Electrocardiography; Female; Fluoroquinolones; Heart; Heart Rate; Humans; Imidazoles; Long QT Syndrome; Male; Moxifloxacin; Phosphodiesterase 5 Inhibitors; Piperazines; Placebos; Quinolines; Sulfones; Tachycardia; Triazines; Vardenafil Dihydrochloride | 2011 |
Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Topics: Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Biomarkers, Pharmacological; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Guidelines as Topic; Heart Rate; Humans; Long QT Syndrome; Male; Moxifloxacin; Naltrexone; Narcotic Antagonists; Placebos; Prospective Studies; Quinolines; Treatment Outcome; Young Adult | 2011 |
QT effect of semagacestat at therapeutic and supratherapeutic doses.
Topics: Administration, Oral; Adult; Aged; Alanine; Amyloid Precursor Protein Secretases; Analysis of Variance; Arrhythmias, Cardiac; Aza Compounds; Azepines; Cross-Over Studies; Electrocardiography; England; Enzyme Inhibitors; Female; Fluoroquinolones; Heart Rate; Humans; Least-Squares Analysis; Male; Middle Aged; Moxifloxacin; Quinolines; Risk Assessment; Risk Factors; Young Adult | 2012 |
Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Topics: Action Potentials; Adolescent; Adult; Anticonvulsants; Arrhythmias, Cardiac; Aza Compounds; Cross-Over Studies; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Heart Rate; Humans; Levetiracetam; Male; Middle Aged; Moxifloxacin; Piracetam; Quinolines; Risk Assessment; Young Adult | 2008 |
18 other study(ies) available for moxifloxacin and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Contribution of haemodynamic side effects and associated autonomic reflexes to ventricular arrhythmias triggering by torsadogenic hERG blocking drugs.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Ether-A-Go-Go Potassium Channels; Heart Rate; Long QT Syndrome; Moxifloxacin; Quinidine; Reflex; Torsades de Pointes | 2022 |
A Computational Pipeline to Predict Cardiotoxicity: From the Atom to the Rhythm.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotoxicity; Cardiotoxins; Computer Simulation; Drug Discovery; ERG1 Potassium Channel; Female; Humans; Long QT Syndrome; Machine Learning; Male; Moxifloxacin; Myocytes, Cardiac; Phenethylamines; Protein Structure, Secondary; Sulfonamides; Topoisomerase II Inhibitors | 2020 |
Modulating the voltage sensor of a cardiac potassium channel shows antiarrhythmic effects.
Topics: Action Potentials; Amino Acid Substitution; Animals; Arrhythmias, Cardiac; Calcium; Dogs; Furans; Gene Expression; Guinea Pigs; Heart Atria; Heart Ventricles; Humans; KCNQ1 Potassium Channel; Moxifloxacin; Myocytes, Cardiac; Oocytes; Patch-Clamp Techniques; Phenethylamines; Potassium; Primary Cell Culture; Pyridines; Pyrimidines; Small Molecule Libraries; Sodium; Sulfonamides; Transgenes; Xenopus laevis | 2021 |
Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome.
Topics: Anesthetics, Inhalation; Animals; Arrhythmias, Cardiac; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoroquinolones; Halothane; Heart Rate; Long QT Syndrome; Male; Moxifloxacin; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Swine; Swine, Miniature; Terfenadine | 2017 |
Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes.
Topics: Arrhythmias, Cardiac; Astemizole; Calcium; Calcium Channel Blockers; Cardiotonic Agents; Cell Differentiation; Cells, Cultured; Digoxin; Dose-Response Relationship, Drug; Drug Discovery; Fluoroquinolones; Induced Pluripotent Stem Cells; Isoproterenol; Moxifloxacin; Myocardial Contraction; Myocytes, Cardiac; Propranolol; Toxicity Tests; Verapamil | 2017 |
Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Arrhythmias, Cardiac; Cefixime; Ciprofloxacin; Cohort Studies; Female; Fluoroquinolones; Heart Arrest; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Protective Factors; Republic of Korea; Risk Factors; Tachycardia, Ventricular; Ventricular Fibrillation; Ventricular Flutter | 2018 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |
Statistical characteristics of moxifloxacin-induced QTc effect.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Controlled Clinical Trials as Topic; Cross-Over Studies; Data Interpretation, Statistical; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Male; Middle Aged; Models, Statistical; Moxifloxacin; Placebo Effect; Quinolines; Reference Values; Reproducibility of Results; Young Adult | 2010 |
Statistical consideration in testing for assay sensitivity in a "thorough" QT study.
Topics: Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Clinical Trials as Topic; Computer Simulation; Cross-Over Studies; Data Interpretation, Statistical; Electrocardiography; Fluoroquinolones; Heart Rate; Humans; Least-Squares Analysis; Models, Statistical; Moxifloxacin; Quinolines; Time Factors | 2010 |
Revisit the combination validation test of Tsong et al. for thorough QT/QTc clinical trials.
Topics: Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Data Interpretation, Statistical; Electrocardiography; Fluoroquinolones; Heart Rate; Humans; Models, Statistical; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Time Factors | 2010 |
Response to letter to the editor: Statistical issues of QT prolongation assessment based on linear concentration modeling by Yi Tsong et al.
Topics: Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Heart Rate; Humans; Linear Models; Models, Statistical; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Time Factors | 2010 |
Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study.
Topics: Adult; Aged; Aging; Animals; Arrhythmias, Cardiac; Aza Compounds; Circadian Rhythm; Female; Fluoroquinolones; Heart Rate; Humans; Inhibitory Concentration 50; Ion Channel Gating; Male; Middle Aged; Models, Biological; Moxifloxacin; Quinolines; Sex Characteristics; Young Adult | 2013 |
QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Topics: Action Potentials; Animals; Anti-Infective Agents; Area Under Curve; Arrhythmias, Cardiac; Aza Compounds; Cell Line; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electrocardiography; Ether-A-Go-Go Potassium Channels; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Moxifloxacin; Phenethylamines; Potassium Channels, Inwardly Rectifying; Quinolines; Rabbits; Sulfonamides; Telemetry; Treatment Outcome | 2005 |
Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Aza Compounds; Cell Line; Dose-Response Relationship, Drug; Erythromycin; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Guinea Pigs; Heart Rate; Humans; Ketolides; Moxifloxacin; Quinolines; Risk Factors; Torsades de Pointes | 2006 |
No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Arrhythmias, Cardiac; Aza Compounds; Azithromycin; Dogs; Dose-Response Relationship, Drug; Electric Stimulation; Electroencephalography; Electrophysiology; Fluoroquinolones; Heart Block; Heart Rate; Long QT Syndrome; Moxifloxacin; Phenethylamines; Quinolines; Sulfonamides; Torsades de Pointes | 2006 |
Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cation Transport Proteins; DNA-Binding Proteins; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Gatifloxacin; Long QT Syndrome; Mice; Models, Animal; Moxifloxacin; Patch-Clamp Techniques; Piperazines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quinolines; Rabbits; Trans-Activators; Tumor Cells, Cultured | 2001 |
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Topics: Action Potentials; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cisapride; Dogs; Erythromycin; Female; Fluoroquinolones; Imidazoles; In Vitro Techniques; Indoles; Long QT Syndrome; Male; Models, Biological; Moxifloxacin; Perfusion; Piperazines; Purkinje Fibers; Quinolines; Sotalol; Swine; Torsades de Pointes | 2001 |